These authors contributed equally to this work.
Introduction
One of the most common malignancies, colorectal cancer (CRC), accounts annually for almost half a million deaths worldwide. Mortality of cases results from uncontrolled metastatic disease, particularly in peritoneum, lymph nodes and liver. Tumor metastasis itself is responsible for ~90% of all CRC-related deaths (1, 2) . The molecular basis of CRC pathogenesis and progression is complicated and poorly understood at present.
Mucinous colorectal carcinoma is generally defined as having greater than 50% of the tumor area with a mucinous differentiation by histologic examination. The incidence of mucinous carcinoma is about 12% among CRC patients, ranging from 6 to 19% in different studies (3) . The increased incidence occurs in proximal colon and among younger patients, as compared to nonmucinous adenocarcinoma. Mucinous CRCs have been found to have a higher Duke stage at diagnosis and, consequently, a lower survival (4) .
Mucins are large extracellular glycoproteins produced by epithelial cells, which are heavily glycosylated with complex oligosaccharides (5, 6) . The core proteins for human mucins (MUC1-MUC8, MUC12, MUC13, MUC15-17 and MUC19- 21) have already been identified (7) . Many mucins are abnormally expressed and aberrantly glycosylated in adenocarcinomas. In general, increased levels of mucin genes have been associated with increased cancer risk, tumor invasion, and a poor patient outcome (8) (9) (10) (11) . Previous studies have found that an upregulation of MUC1 and MUC5AC and a down-regulation of MUC2 are involved in the development and progression of CRC (3, 12, 13) . Recently, the overexpression of MUC20 was considered as a predictor of poor prognosis in CRC (10) . In CRC, the overexpression of transmembrane mucins suggests their role in signaling cell growth and survival. Mucins have thus been identified as markers of adverse prognosis (6) .
Interestingly, recent studies have unraveled a role of microRNAs (miRNAs) also in the regulation of various mucins (14) . MiRNAs are short (20-22 nucleotide) non-coding RNAs that regulate gene expression by binding mainly to the 3′ untranslated regions (3′ UTR) of target mRNA thereby hampering protein translation or inducing mRNA destabilization. Aberrant miRNA expression and/or function are frequently observed in many malignancies, including CRC (15) . The increasing need for newer diagnostic strategies to target tumors has led to the appearance of miRNAs as potential cancer therapeutics of new generation. Moreover, genetic variations in the 3′ UTR of target genes may affect miRNA binding, ultimately adding additional variability in the differential mRNA and protein expressions.
We recently reported associations between single nucleotide polymorphisms (SNPs) in miRNA target regions of DNA repair pathway genes and CRC risk or clinical outcome (16) (17) (18) (19) . In the present study, we hypothesized that genetic variations in mucin genes may also affect cancer susceptibility, patient's survival and efficacy of chemotherapy. SNPs in miRNA target regions (miRSNPs) of mucin genes might affect the efficiency of translation of corresponding proteins, thus affecting individual's susceptibility to cancer. So far, the impact of miRSNPs in mucin genes on the CRC risk has not been tested yet. We have studied this assumption in patients with CRC from the Czech Republic, a country with one of the highest incidence worldwide for this cancer (20) .
Material and methods

Study population and data collection
Blood samples were collected from 1111 patients with histologically confirmed CRC attending several oncological departments in the Czech Republic [Prague (3 hospitals), Benesov, Brno, Liberec, Ples, Pribram, Usti nad Labem and Zlin] between September 2003 and October 2010. Two control groups, whose samples were collected at the same time of cases recruitment, were included in the study. The first group consisted of 688 hospital-based individuals admitted to five of the above-mentioned gastroenterological departments that had negative colonoscopy results for malignancy or idiopathic bowel diseases (Control group 1). The reasons for undergoing the colonoscopy were: (1) positive fecal occult blood test, (2) hemorrhoids, (3) abdominal pain of unknown origin and (4) macroscopic bleeding. The second group of controls consisted of 781 healthy blood donor volunteers (Control group 2) collected from a blood donor centre in Prague. All individuals were subjected to standard examinations to verify the health status for blood donation and were cancer-free at the time of the sampling. Details of CRC cases and controls have been reported previously (18) .
All subjects were informed and provided written consent to participate in the study and to approve the use of their biological samples for genetic analyses, according to the Helsinki declaration. The local Ethics Committee approved the design of the study. Study subjects provided information on their lifestyle habits, body mass index (BMI), diabetes and family/personal history of cancer, using a structured questionnaire to determine demographic characteristics and potential risk factors for CRC.
Follow up of patients
Eight hundred sixty-six CRC cases and a second group consisting of 232 CRC patients recruited later on were monitored and followed up until 31st March 2013. For all subjects, clinical data at the time of diagnosis, including location of the tumor, UICC (International Union Against Cancer) tumor-node metastasis stage system, grade and adjuvant chemotherapy treatment were collected, along with information about distant metastasis, relapse and date of death (21) . In our patients dataset, a subgroup of patients (n = 47) was diagnosed with mucinous cancer.
Four hundred and eleven CRC cases received a 5-FU-based adjuvant regimen as first-line postoperative therapy. The therapy was based on either a Mayo regimen, delivered as a bolus infusion of 5-FU (425 mg/m 2 ) and leucovorin (10 mg/m 2 ) for five days every four weeks six times or a simplified De Gramont regimen which consisted of a 2-h intravenous (i.v.) infusion of leucovorin (200 mg/m 2 ), then a 5-FU i.v. bolus (400 mg/m 2 ) followed by a 46-h 5-FU continuous i.v. infusion (2400-3000 mg/m 2 ). Four hundred forty subjects did not receive any adjuvant chemotherapy after surgery.
Selection of candidate genes and SNPs in miRNA target binding sites
The list of all mucin genes was retrieved by literature mining (3, 6, 7) . The approach used to select the candidate miRSNPs was similar to the one previously described (18) . Briefly, for each gene, SNPs within predicted miRNA binding sites were identified by using the freely available software: MicroSNiper (http://epicenter.ie-freiburg.mpg.de/services/microsniper/), Mirnsnpscore (http://www.bigr.medisin.ntnu.no/mirsnpscore/) and Polymirt (http://compbio.uthsc.edu/miRSNP/). The 59 detected SNPs were then filtered for their minor allele frequency (MAF> 5%) in Caucasian populations (dbSNP; http://www.ncbi.nlm.nih.gov/SNP/) to reach an appropriate representation of all genotypes in our set of cases and controls. The information was primarily derived from 1000genomes project database, phase 1, CEU population; whenever this was not possible, other reference populations were considered (i.e. HAPMAP CEU population). SNPs with the required MAF were further tested for the possibility to be in linkage disequilibrium (LD) using HaploView (v. 4.2) with the data from HapMap (v. 3, release R2 in the CEU population).
SNP genotyping
Genomic DNA was isolated from peripheral blood lymphocytes using standard procedures. The DNA from cases and controls was randomly placed on plates where an equal number of samples could be run simultaneously. The selected SNPs were genotyped using the KASP TM genotyping assay, a competitive allele-specific PCR SNP genotyping system (LGC Genomics, Hoddesdon, Herts, UK). For quality control purposes, duplicate samples (5% of the total numbers of samples) were repeated for each SNP, no template controls were included in each plate (NTCs). The model with the highest likelihood was additionally checked for the significance of possible interaction terms in the multivariate logistic regression analysis. Statistical analyses were performed using R (http:// www.rproject.org).
Abbreviations
In this study, the outcome variables measured were overall survival (OS, time from diagnosis until death or censorship), and event-free survival (EFS, time of surgery or end of chemotherapy until date of relapse, death or censorship whichever came first). The survival curves for OS and EFS were derived by the Kaplan-Meier method (R version 2.14-2, Survival package). The relative risk of death was estimated as hazard ratio (HR) using Cox regression (R version 2.14-2, Survival package). Multivariate survival analyses were adjusted for age, gender, smoking and stage.
Results
miRSNP selection
Out of the 20 genes categorized as human mucins, only 12 had miRSNPs in their 3′ UTRs (62 miRSNPs retrieved). For three of them we could not retrieve any information. The remaining 59 miRSNPs were filtered according to the study criteria previously described (i.e. MAF and LD). In total, 46 SNPs were excluded. 
Case-control study
The characteristics of the study participants are presented in Table 1 . Among the 1111 CRC cases, 397 patients were diagnosed with a tumor in colon, 334 in sigmoideum and 377 with rectal cancer (3 cases were missing the information about the site of tumor; however, since they had complete survival data, they remained in the survival analysis). Out of the 1469 controls, 688 were cancer-free colonoscopy inspected controls (Control group 1) and 781 were healthy blood donor volunteers (Control group 2). Compared to subjects of both control groups, CRC cases were more likely to be older, have a slightly higher BMI while, compared to the Control group 2, they were more likely to have a positive family history of CRC and lower formal education ( Table 1) .
Results of the associations between the investigated miRSNPs and CRC susceptibility are reported in Supplementary 95% CI 0.04-0.81, P = 0.02; for the variant A allele OR 0.18, 95% CI 0.04-0.80, P = 0.02). An association with CRC risk was observed for a SNP in MUC13. The variant AA genotype of rs1532602 was in fact associated with a decreased risk of cancer (OR 0.75, 95% CI 0.56-1.00, P = 0.05). After stratification according to the tumor site, the association was still observed in colon cancer patients (OR 0.72, 95% CI 0.51-1.00, P = 0.05), and resulted stronger for the dominant model (OR 0.79, 95% CI 0.63-0.99, P = 0.04). Finally, a decreased risk of CRC was observed in a recessive model for rs974034 in MUC24 (OR 0.76, 95% CI 0.58-1.00, P = 0.05). None of the above associations remained significant after applying correction for multiple testing (Bonferroni's correction).
We have also repeated the analyses in the subgroup of patients with diagnosed mucinous CRC histology (47 patients). However, in this subgroup of patients, we did not find any significant association with the CRC risk for any of the analyzed SNPs (data not shown). This last result should be cautiously considered due to the low frequency of mucinous CRC in our study group.
Survival analysis
The mean (median) OS and EFS for patients were 86.5 (80.5) and 72.6 (62.4) months, respectively. Age, gender, T, N, M status, chemotherapy treatment and CRC stage were associated with OS and EFS in the preliminary univariate assessment of covariates (Table 2 ). Advanced age, male gender and current smoking status were related to a shorter OS. Likewise, men were also at higher risk of relapse or metastasis (OS: HR 1.54; 95% CI 1.23-1.92; P = 0.0001; EFS: HR 1.35; 95% CI 1.09-1.68; P = 0.006).
Four established prognostic factors (T, N, M status and stage)
were associated with decreased patients' survival and increased risk of recurrence. Moreover, adjuvant chemotherapy was also associated with survival (Table 2) .
After adjusting for sex, age, smoking and CRC stage, the strongest association with patient´s survival was observed for rs886403 in MUC21 (Tables 3 and 4) . CRC patients carrying the CC genotype displayed a shorter survival and higher recurrence risk (OS: HR 1.69; 95% CI 1.13-2.46; P = 0.01 and EFS: HR 1.99; 95% CI 1.38-2.84; P = 0.0002, respectively) when compared with carriers of the most frequent genotype. The observed associations were more striking, after stratification for tumor site, in patients with colon cancer (OS: HR 2.63; 95% CI 1.69-4.10; P < 0.0001 and EFS: HR 2.65; 95% CI 1.72-4.07; P = 0.0001 and in the recessive model OS: HR 2.70; 95% CI 1.77-4.12; P < 0.0001 and EFS: HR 2.43; 95% CI 1.61-3.64; P < 0.0001). Particularly for EFS, CRC patients also showed a similar significant trend across genotypes in the Kaplan-Meier curves (log-rank test P = 0.03; Median survival time for TT carriers=353 months; MST for CT =231 months; MST for CC carriers=79 months; Figure 1A) . A similar trend was found also for colon cancer patients (log-rank test P = 0.03; MST for CC carriers = 115 months; MST not reached for the other genotypes; Figure 1B ) but not for rectal cancer patients ( Figure 1C) .
Among colon cancer patients, carriers of the TC genotype of MUC6 rs4077531 showed a decreased survival (OS: HR 1.38; 95% CI 1.00-1.90; P = 0.05). On the other hand, individuals with rectal cancer and carrying variant CC genotype of rs4729655 in MUC17 displayed a longer survival when compared with the reference genotype (OS: HR 0.27; 95% CI 0.14-0.54; P = 0.0002). Overall, rectal cancer patients also showed a similar significant trend across genotypes in the Kaplan-Meier curves (log-rank Table 4 . Continued test P = 0.002; MST for TT carriers = 67 months; MST for TC carriers=152; MST for CC carriers=176; Figure 2C ). For the same variant genotype, CRC patients showed also better survival in a recessive model (OS: HR 0.73; 95% CI 0.55-0.98; P = 0.03). Conversely, no significant changes in survival were observed in CRC patients and in colon cancer patients in the univariate model (Figure 2A and B) . Finally, CRC and colon cancer patients carrying variant GG genotype of rs6782006 in MUC20 showed worse survival (OS: HR 1.80; 95% CI 1.10-2.97; P = 0.02 and HR 1.90; 95% CI 1.00-3.69; P = 0.05, respectively).
Discussion
Mucins are high molecular weight glycoproteins predominantly expressed at the epithelial surface of tissues that provide protection for colon surface under normal physiological conditions (22) . Several lines of evidence point towards a biological role of mucins in CRC (22, 23) . These include: observations on mucinous CRC in in vitro and in vivo experiments and alterations of mucin structure in polyps and cancer. Although mucinous CRC have a higher Dukes stage at diagnosis and show a worse prognosis, the cause of such negative phenotypes is not comprehensively elucidated. Mucins have an important role in epithelial cell protection and maintenance of homeostasis by covering human colon surface by gel mucous layer. Lower cell adhesion may contribute to incorrect cellular organization and structure, proliferation and survival, and ultimately gene expression alteration. The appropriate cell adhesion is necessary for numerous physiological processes and can be deranged in many diseases, including thrombosis, inflammation, and cancer (24) . Recently, miRNAs have emerged as important regulators responsible for an altered mucin expression during the malignant development (14) . To date, no study has investigated the impact of miRSNPs within mucin genes on CRC susceptibility or clinical outcome. In the present study, we have found that some miRSNPs in mucin genes were associated with CRC risk and they had an impact on patient´s survival. Interestingly, a reduced CRC risk was observed for individuals bearing homozygous variant genotypes of MUC13 rs1532602, EMCN/MUC14 rs4071 and rs17552409 and MUC24 rs974034. After stratification for tumor localization, some of these results were confirmed in colon cancer patients (rs1532602 in MUC13, in a dominant model) or rectal cancer patients (rs4071 in EMCN/MUC14 in recessive model). After applying correction for multiple testing, these associations were lost. On the other hand, such conservative correction may not be required considering: (1) the exploratory nature of our study, (2) the fact that all the SNPs were selected for their high prior probability of functional significance, and (3) based on differential binding of miRNAs to their predicted polymorphic target sites. Both EMCN/MUC14 rs4071 and rs17552409 polymorphisms were also tested for their potential SNP-SNP interaction on CRC susceptibility. No effect on CRC risk was observed when these two SNP were analyzed together. Similarly, we have also repeated the analyses in the subgroup of patients with diagnosed mucinous CRC histology. However, due to the low representation of mucinous CRC in this subgroup of patients (47 patients), we did not find any significant association with the CRC risk for any of the analyzed SNPs. Mucinous CRC tends to occur in younger patients, are often seen in the proximal colon, are more diagnosed at an advanced stage and are more frequently associated with hereditary non-polyposis colorectal cancer (HNPCC) and young-age sporadic colorectal cancer. The low proportion of mucinous CRC patients in the present study could be inflicted The stronger and novel finding of this study is represented by the associations of some miRSNPs with clinical outcome. In particular, CRC patients carrying the CC genotype for rs886403 in MUC21 displayed a shorter survival and higher recurrence risk. The observed association was strikingly pronounced in colon cancer patients. MUC21 has been identified quite recently (25) . The gene encodes for a transmembrane mucin related to the biosynthesis of N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO). According to STRING Interaction Network (www.genecards.org), there is a close cooperation among MUC21 and MUC17, MUC20, MUC16, GALNT5 and ST3GAL3. Scarce information is available for this gene, thus the postulation of hypothesis that this gene might be associated with patient´s survival is quite difficult. Cells transfected by MUC21 were significantly less adherent to each other and to extracellular matrix components than control cells, suggesting that MUC21 prevents integrin-mediated cell adhesion to extracellular matrix components (26) . Cell adhesion and cell-cell interactions also play vital roles in many later steps in cancer progression, facilitating the entry and survival of cancer cells into the bloodstream, and their arrest and establishment at distant organs (24) . The miRNA-mediated regulation of MUC21 expression has not been investigated yet. Several miRNAs (such as miR-4647, miR-588, miR-125 and let-7) are predicted to bind in the region surrounding rs886403. However, none of them have been validated in relation to MUC21, so far.
In this study, rectal cancer patients carrying the CC genotype of MUC17 rs4729655 displayed a better OS when compared with the carriers of the other genotypes. MUC17, an intestinal membrane-bound mucin, has been shown to enhance mucosal restitution by stimulation of cell migration and inhibition of apoptosis (27) . MUC17 is highly expressed on the surface epithelium of normal colonic mucosa but its expression becomes altered in colorectal neoplasia. Interestingly, an increased expression of MUC17 was associated with a longer OS in patients with stage III and IV colorectal adenocarcinomas (28) . These results point to its possible role in cancer progression and prognosis. Although the physiological function of MUC17 is still unclear, it may serve as a physical barrier against microorganisms and as cell-surface sensor. MUC17 may also conduct signals in response to external stimuli that lead to cellular responses, including proliferation, differentiation, apoptosis or secretion of cellular products such as other membrane-bound mucins (29) . Kitamoto et al. (29) proposed several miRNAs as potential regulators of MUC17 expression, but none of them has been validated in vivo.
As there is an established interplay between MUC21 and MUC17 genes according to STRING, the polymorphisms significantly associated emerging from the follow up study were also explored for their potential SNP-SNP interaction on patients survival. However, no effect was observed for these two particular genes in combination.
A strong association with either shorter OS or EFS was observed for MUC20 gene (rs6782006). CRC patients, particularly those with colon cancer, carrying the variant GG genotype of this miRSNP had worse survival. MUC20 is a novel mucin protein highly expressed in kidney and colon tissues. Based on wholegenome expression profiling of CRC, MUC20 was significantly upregulated in CRC patients with poor prognosis (10) . A relationship between MUC20 overexpression and poor survival was found in many human tumors, including ovarian cancer (30) , non-small cell lung cancer (31) , and gastric cancer (32) . MUC20 overexpression predicts poor prognosis in endometrial cancer and enhances EGF-triggered invasive behavior through activation of EGFR-STAT3 pathway (33) . Increased expression levels of MUC20 promoted metastasis of CRC cells, whereas knockdown of this gene attenuated migration and invasion abilities of CRC cells (10) . Like for the other mucin genes, the number of studies regarding miRNA-mediated control of the expression of MUC20 is still scarce.
From a clinical point of view, malignancies in the colon and the rectum represent two distinct entities that require different treatment strategies. The distinction between colon and rectum is largely anatomical but it impacts both surgical and radiotherapeutic management with often different prognoses. This has been already observed by us in a previous study on rectal cancer (34) but it emerged also from the results of the present study. There are in fact different survival rates associated to the different kind of cancer site and specific miRSNPs. Our data contributes to improved understanding of the role of specific miRSNPs in rectal and colon cancer pathogenesis. Treating the 2 sites as independent entities may improve discovery of biomarkers used for early detection and prognosis.
We are aware of certain limitations of the present investigation. In the case-control study, healthy subjects differed from cases in age and gender distribution, as well as other parameters such as BMI. However, we attempted to control tentative age effect by matching cases and controls by age quartiles through bootstrap sampling (830 cases and 830 controls). In particular, we obtained similar results to those presented in this work in 8 out of 10 resamplings. Moreover, patients were collected from the same centers (with follow up data collected by the same physicians) and were highly homogeneous for their ancestry, thus with the exclusion of possible population stratifications. In addition, the inclusion of 'colonoscopy negative' individuals ensured disease-free control individuals because a negative colonoscopy result is the best available proof of the CRC absence (35) . Nevertheless, there is concern that the colonoscopy negative control group is based on existing medical conditions of patients, which required examination and thus may carry unknown CRC risk factors. Since this group of individuals may not necessarily represent the general population, we included also healthy cancer-free individuals recruited among volunteers from blood centers. However, there were no statistically significant differences in genotypes frequencies of mucin genes between the two control groups, which allowed pooling of the controls to increase the statistical power of the study.
Mucin synthesis and secretion by CRC affects the phenotype of the disease, as demonstrated in vitro and in vivo. Expanding our knowledge on mucin involvement in CRC may help us to better understand the etiopathogenesis of this disease and thereby contribute to the development of new treatment strategies. It is well known that mucinous CRC have a higher Dukes stage at diagnosis and a worse prognosis. The present results identified plausible candidate SNPs potentially affecting miRNA binding in mucin genes that were related either to CRC susceptibility or to patient's survival. Moreover, our study supports the emerging idea of a 'miRNA network' that may contribute to CRC. Further studies are needed to replicate these SNPs as predictive biomarkers in independent populations, to functionally characterize the significant genetic variants and to find the biologic mechanisms underlying the associations.
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